CD8A and hepatocellular carcinoma: PVRL1 upregulated by HCC cells stabilizes PVR on the cell surface, which interacts with the inhibitory molecule TIGIT of CD8 effector memory T cells. It is possible to develop PVRL1/TIGIT inhibitors as well as anti-PD1 to treat HCC.